CLINICAL-STAGE PIPELINE
Lenzilumab
Ifabotuzumab
HGEN005
Indication
Phase
Status
Centers
Partners
47 sites
3
Undisclosed
Up to 23 sites
2
10 sites
Including MD Anderson and other ZUMA-1 sites
ZUMA-19
Break CAR-T Efficacy/Toxicity Linkage
Lenz prophylaxis as sequenced therapy with Yescarta in r/r DLBCL
Phase Ib/II
1
Active, recruiting
Chronic myelomonocytic leukemia (CMML)
Lenz + azacitidine in NRAS, KRAS or CBL mutant-positive newly-diagnosed patients
Phase II
Advanced Planning
Prevention/Treatment of Acute GvHD
Allogeneic HSCT
Phase II/III
Advanced Planning
Eosinophilic Asthma (EA)
Lenz in inadequately controlled asthma
Phase II
Completed, seeking partner for Phase III
CMML
Lenz monotherapy in salvage patients
Phase I
Completed
To Be Determined
COVID-19
Lenz in prevention/treatment of cytokine storm leading to acute respiratory distress syndrome (ARDS)
Phase III
Planning
4
Solid Tumors
(Glioblastoma Multiforme)
Phase I
Active, almost fully recruited
EA and other eosinophilic diseases
Preclinical
Seeking partner for Phase I/II
1 Phase III may not be necessary for approval in ZUMA-19; precedent is CAR-Ts to date have been approved on Phase II data
2 UK
3 US, EU, Australia
4 Australia